News zum Sektor Gesundheit aus Australien & Ozeanien

 

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

Pro Medicus and Droneshield are both popular ASX growth shares, but only one stands out for quality and momentum right now. The post Droneshield vs Pro Medicus: Which is the better ASX growth stock right now? appeared first on The Motley Fool Australia....

The drug maker is a standout among these companies. The post Buy, hold, sell: Mesoblast, Dicker Data, ASX shares appeared first on The Motley Fool Australia....

Second of Four Planned Modules Moves Rolling FDA Review ForwardAdvances Toward Targeted Completion of the Final Clinical Module Submission in Q2 2027White Bear Lake, Minnesota--(Newsfile Corp. - Oc......

WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on October 9, 2026, driven by catalysts such as achieving new regulatory milestones.Humana Inc. (HUM)Humana functions as ......

The HARNESS-1 Safety Review Committee identified no dose-limiting toxicities or treatment-related safety concerns in either Cohort 1 patient during the safety observation period and has recommended the trial proceed to the next planned dose level of RC220 in combination with osimertinib.......

The shares have recovered sharply, so I wanted to see whether the valuation still stacks up. The post CSL shares: Buy, hold, or sell? appeared first on The Motley Fool Australia....

Racura Oncology can escalate RC220 to 100mg/sqm in its lung cancer trial after no safety concerns emerged at the initial dose....

Digital cognitive assessment player Cogstate (ASX:CGS) has seen its shares jump nearly…...

The market has started the new week in the green. The post Buy, hold, sell: Mesoblast, Transurban, NextDC shares appeared first on The Motley Fool Australia....

Let's start the week with some fresh ratings from the experts.  The post Buy, hold, sell: Resmed, Megaport, ANZ shares appeared first on The Motley Fool Australia....

Total sales were up 10%, and resales growth outpaced last year. The post Summerset Group Q3 FY26 earnings: Sales up 10% on strong resales appeared first on The Motley Fool Australia....

Racura Oncology (ASX:RAC) has been greenlit by a safety committee to increase…...

We compare Telix and Clinuvel Pharmaceuticals on valuation, dividends, and momentum—which ASX healthcare stock looks more compelling now? The post Telix vs Clinuvel Pharmaceuticals: Which ASX healthcare share deserves your next $1,000 of investment capital? appeared first on The Motley Fool Australia....

We pit CSL against Commonwealth Bank to see which ASX blue chip offers SMSFs the best mix of dividends, franking, and value right now. The post CSL vs CBA: Which ASX share is best for SMSFs? appeared first on The Motley Fool Australia....

CSL's segments deliver strong revenue growth, while acquisitions and shareholder returns support expansion despite rising raw-material costs and margin pressures....

CANBERA (dpa-AFX) - Friday, Profound Medical Corp. (PROF) and Telix Pharmaceuticals Limited (TLX) announced a co-education agreement to educate physicians and prostate cancer centers on the comple......

Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix's PSMA-PET molecular imaging technologies and Profound's MRI-guided TULSA-PRO®...

MELBOURNE, Australia and SAN FRANCISCO, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will present at the Canaccord Genuity Drug and Device Conference on Monday, October 12, 2026 at 3:50 p.m. AEST in Australia....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...